Counted the retatrutide threads on this board. Almost none distinguish content verification from outcome. That is the whole argument.
My rule now: if a claim cannot survive being written down with the numbers attached, it is marketing.
Most of the popular protocols are borrowed from clinical populations and applied to healthy people without comment.
What the GLP-1 class does pharmacologically does not require the subjective effect to be large to be real.
If you need three other compounds to notice the first one, you have not tested the first one.
Titration is slow by design and rushing it is how people end up miserable.
Interested in the methods more than the conclusion.
Narrow conclusion, briefly right. Broad conclusion, interestingly wrong. I know which I keep choosing.